VJOncology is committed to improving our service to you

GU Cancers 2020 | Enfortumab vedotin with pembrolizumab for bladder cancer

VJOncology is committed to improving our service to you

Guru Sonpavde

Guru Sonpavde, MD, Dana-Farber Cancer Institute, Boston, MA, outlines his research highlights from the 2020 ASCO GU meeting. Dr Sonpavde discusses the combination of enfortumab vedotin and pembrolizumab for metastatic urothelial carcinoma as well as the ATLAS trial (NCT03397394). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter